A-SKIN was founded in January 2006 as a spin-off company of the VU university medical center in Amsterdam. A-SKIN’s objective is to become a leading company for the development and production of in vitro cultured skin tissues and related products for skin wounds, in particular chronic open wounds.
In the period 2004-2009 A-SKIN obtained very promising results in clinical pilot studies with its first skin product Tiscover® in chronic leg ulcer patients. After a subsequent change in European legislation for the clinical treatment with tissue products, the culture method, laboratory facilities and – personnel were brought up to the required levels to meet the new standards. A new clinical phase-II study was started in 2012 by the VU Medical Center (VUmc) with support of the Department of Economic Affairs and participation of A-SKIN as manufacturer of Tiscover®. The Inspectie Gezondheidszorg (IGZ; Healthcare Inspection) granted A-SKIN the manufacturing license and the license according to the legislation for Safety and Quality of Human Organs for transplantation.
In parallel to the clinical phase-II study on the efficacy of Tiscover®, research continues on a number of sophisticated off-the-shelf products for the treatment of skin wounds.
For information about investment opportunities in A-SKIN B.V. please contact email@example.com
Chamber of Commerce: A-SKIN Holding BV: 34240016, registration January 9th 2006
Chamber of Commerce: A-SKIN Nederland BV 34240022, registration January 9th 2006